Biogency Synext Lite

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

nicotinamide, Quantity: 20 mg; pyridoxine hydrochloride, Quantity: 300 microgram (Equivalent: pyridoxine, Qty 250 microgram); Biotin, Quantity: 600 microgram; cyanocobalamin, Quantity: 10 microgram; folic acid, Quantity: 120 microgram; ubidecarenone, Quantity: 30 mg; leucine, Quantity: 60 mg; heavy magnesium oxide, Quantity: 30 mg (Equivalent: magnesium, Qty 18 mg); nicotinic acid, Quantity: 70 mg; Curcuma longa, Quantity: 120 mg (Equivalent: Curcuma longa, Qty 2.4 g); chromium picolinate, Quantity: 64.4 microgram (Equivalent: chromium, Qty 8 microgram); riboflavin, Quantity: 600 microgram; quercetin, Quantity: 120 mg; Piper nigrum, Quantity: 4 mg (Equivalent: Piper nigrum, Qty 200 mg); Reynoutria japonica, Quantity: 36 mg (Equivalent: Reynoutria japonica, Qty 3.6 g)

Available from:

Biogency Pty Ltd

Pharmaceutical form:

Tablet, film coated

Composition:

Excipient Ingredients: microcrystalline cellulose; magnesium stearate; silicon dioxide; crospovidone; croscarmellose sodium; povidone; calcium hydrogen phosphate dihydrate; titanium dioxide; brilliant blue FCF aluminium lake; tartrazine; hypromellose; macrogol 400

Administration route:

Oral

Therapeutic indications:

Maintain/support energy production ; Anti-inflammatory/relieve inflammation ; Maintain/support cardiovascular system health ; Maintain/support healthy cardiovascular system function ; Maintain/support blood capillary health ; Maintain/support (state vitamin/mineral/nutrient) levels in the body

Product summary:

Visual Identification: ;

Authorization status:

Listed

Authorization date:

2019-08-02